Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Standard BioTools Inc. (Nasdaq:LAB) has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City. The company's President and CEO, Michael Egholm, PhD, will present at a fireside chat on Friday, September 6, 2024, at 8:30 a.m. ET.
The presentation will be webcast live on the company's Investor Relations page under Events & Presentations. A recording of the webcast will also be archived and available for later viewing at investors.standardbio.com. This conference, running from September 4th to 6th, provides Standard BioTools with an opportunity to showcase its developments and engage with industry professionals and investors.
Standard BioTools Inc. (Nasdaq:LAB) ha annunciato la sua partecipazione al 22° Annual Global Healthcare Conference di Morgan Stanley a New York City. Il Presidente e CEO dell'azienda, Michael Egholm, PhD, interverrà in una chat informale venerdì 6 settembre 2024, alle 8:30 ET.
La presentazione sarà trasmessa in diretta sulla pagina delle Relazioni con gli Investitori dell'azienda, nella sezione Eventi e Presentazioni. Una registrazione della trasmissione sarà inoltre archiviata e disponibile per visionarla successivamente su investors.standardbio.com. Questa conferenza, in programma dal 4 al 6 settembre, offre a Standard BioTools l'opportunità di mostrare i propri sviluppi e interagire con professionisti del settore e investitori.
Standard BioTools Inc. (Nasdaq:LAB) ha anunciado su participación en la 22ª Conferencia Anual Global de Atención Sanitaria de Morgan Stanley en la ciudad de Nueva York. El Presidente y CEO de la compañía, Michael Egholm, PhD, presentará en una charla informal el viernes 6 de septiembre de 2024, a las 8:30 a.m. ET.
La presentación será transmitida en vivo en la página de Relaciones con Inversores de la empresa en la sección de Eventos y Presentaciones. También se archivará una grabación de la transmisión para su visualización posterior en investors.standardbio.com. Esta conferencia, que se llevará a cabo del 4 al 6 de septiembre, proporciona a Standard BioTools la oportunidad de mostrar sus desarrollos e interactuar con profesionales de la industria e inversores.
스탠다드 바이오툴스 Inc. (Nasdaq:LAB)가 뉴욕시에서 열리는 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 사장 겸 CEO인 마이클 에글홀름, PhD가 2024년 9월 6일 금요일, 오전 8시 30분 ET에 진행되는 파이어사이드 챗에서 발표할 예정입니다.
프레젠테이션은 회사의 투자자 관계 페이지의 이벤트 및 프레젠테이션 섹션에서 실시간으로 방송됩니다. 방송의 녹화본도 아카이브되어 추후 investors.standardbio.com에서 시청할 수 있습니다. 9월 4일부터 6일까지 열리는 이번 컨퍼런스는 스탠다드 바이오툴스에게 자사의 개발 사항을 소개하고 산업 전문가 및 투자자들과 소통할 수 있는 기회를 제공합니다.
Standard BioTools Inc. (Nasdaq:LAB) a annoncé sa participation à la 22ème Conférence Annuelle Mondiale sur les Soins de Santé de Morgan Stanley à New York. Le Président et CEO de l'entreprise, Michael Egholm, PhD, interviendra lors d'une discussion informelle le vendredi 6 septembre 2024, à 8h30 ET.
La présentation sera diffusée en direct sur la page des Relations Investisseurs de l'entreprise dans la section Événements et Présentations. Un enregistrement de la diffusion sera également archivé et disponible pour visionnement ultérieur sur investors.standardbio.com. Cette conférence, qui se déroule du 4 au 6 septembre, offre à Standard BioTools l'occasion de présenter ses développements et d'interagir avec des professionnels du secteur et des investisseurs.
Standard BioTools Inc. (Nasdaq:LAB) hat seine Teilnahme an der 22. Jahrestagung von Morgan Stanley zur globalen Gesundheitsversorgung in New York City angekündigt. Der Präsident und CEO des Unternehmens, Michael Egholm, PhD, wird am Freitag, den 6. September 2024, um 8:30 Uhr ET an einem Fireside-Chat teilnehmen.
Die Präsentation wird live übertragen auf der Investor-Relations-Seite des Unternehmens unter Veranstaltungen & Präsentationen. Eine Aufzeichnung der Übertragung wird ebenfalls archiviert und kann später unter investors.standardbio.com angesehen werden. Diese Konferenz, die vom 4. bis 6. September stattfindet, bietet Standard BioTools die Gelegenheit, seine Entwicklungen zu präsentieren und mit Fachleuten aus der Branche sowie Investoren in Kontakt zu treten.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference taking place Wednesday September 4th to Friday September 6th in New York City. Dr. Egholm’s fireside chat will be held Friday, September 6, 2024, at 8:30 a.m. ET.
The presentation will be webcast live and available on the Investor Relations page of the Company’s website at Events & Presentations. A recording of the webcast will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms. Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact:
David Holmes
Gilmartin Group LLC
(332) 330-1031
ir@standardbio.com
FAQ
When is Standard BioTools (LAB) presenting at the Morgan Stanley Healthcare Conference?
Who will be representing Standard BioTools (LAB) at the Morgan Stanley conference?
How can investors watch Standard BioTools' (LAB) presentation at the Morgan Stanley conference?
What are the dates for the Morgan Stanley 22nd Annual Global Healthcare Conference where Standard BioTools (LAB) is presenting?
